Literature DB >> 18957498

Effect of glucagon-like peptide-1 on beta- and alpha-cell function in isolated islet and whole pancreas transplant recipients.

Michael R Rickels1, Rebecca Mueller, James F Markmann, Ali Naji.   

Abstract

CONTEXT: Glucose-dependent insulin secretion is often impaired after islet transplantation where reduced beta-cell secretory capacity indicates a low functional beta-cell mass.
OBJECTIVE: We sought to determine whether glucagon-like peptide-1 (GLP-1) enhanced glucose-dependent insulin secretion and glucagon suppression in islet recipients, and whether GLP-1 effects were dependent on functional beta-cell mass by simultaneously studying recipients of whole pancreas transplants.
SETTING: The study was performed in a clinical and translational research center. PARTICIPANTS: Five intraportal islet and six portally drained pancreas transplant recipients participated in the study. INTERVENTION: Subjects underwent glucose-potentiated arginine testing with GLP-1 (1.5 pmol . kg(-1) . min(-1)) or placebo infused on alternate randomized occasions, with 5 g arginine injected under basal and hyperglycemic clamp conditions.
RESULTS: Basal glucose was lower with increases in insulin and decreases in glucagon during GLP-1 vs. placebo in both groups. During the hyperglycemic clamp, a significantly greater glucose infusion rate was required with GLP-1 vs. placebo in both groups (P < 0.05), an effect more pronounced in the pancreas vs. islet group (P < 0.01). The increased glucose infusion rate was associated with significant increases in second-phase insulin secretion in both groups (P < 0.05) that also tended to be greater in the pancreas vs. islet group (P = 0.08), whereas glucagon was equivalently suppressed by the hyperglycemic clamp during GLP-1 and placebo infusions in both groups. The GLP-1-induced increase in second-phase insulin correlated with the beta-cell secretory capacity (P < 0.001). The proinsulin secretory ratio (PISR) during glucose-potentiated arginine was significantly greater with GLP-1 vs. placebo infusion in both groups (P < 0.05).
CONCLUSIONS: GLP-1 induced enhancement of glucose-dependent insulin secretion, but not glucagon suppression, in islet and pancreas transplant recipients, an effect dependent on the functional beta-cell mass that may be associated with depletion of mature beta-cell secretory granules.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18957498      PMCID: PMC2630873          DOI: 10.1210/jc.2008-1806

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

1.  Elevated portal vein drug levels of sirolimus and tacrolimus in islet transplant recipients: local immunosuppression or islet toxicity?

Authors:  Niraj M Desai; John A Goss; Shaoping Deng; Bryan A Wolf; Eileen Markmann; Maral Palanjian; Angela P Shock; Sue Feliciano; F Charles Brunicardi; Clyde F Barker; Ali Naji; James F Markmann
Journal:  Transplantation       Date:  2003-12-15       Impact factor: 4.939

2.  Proinsulin, insulin, and C-peptide concentrations in human portal and peripheral blood.

Authors:  D L Horwitz; J I Starr; M E Mako; W G Blackard; A H Rubenstein
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

3.  Differential effects of glucagon-like peptide-1 (7-36)amide versus cholecystokinin on arginine-induced islet hormone release in vivo and in vitro.

Authors:  A Guenifi; B Ahrén; S M Abdel-Halim
Journal:  Pancreas       Date:  2001-01       Impact factor: 3.327

4.  Cross-sectional and prospective association between proinsulin secretion and graft function after clinical islet transplantation.

Authors:  Charlotte G McDonald; Edmond A Ryan; Breay W Paty; Peter A Senior; Sally M Marshall; Jonathan R T Lakey; A M James Shapiro
Journal:  Transplantation       Date:  2004-09-27       Impact factor: 4.939

5.  Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets.

Authors:  Adam Frank; Shaoping Deng; Xiaolun Huang; Ergun Velidedeoglu; Yong-Suk Bae; Chengyang Liu; Peter Abt; Robert Stephenson; Muhammad Mohiuddin; Thav Thambipillai; Eileen Markmann; Maral Palanjian; Marty Sellers; Ali Naji; Clyde F Barker; James F Markmann
Journal:  Ann Surg       Date:  2004-10       Impact factor: 12.969

Review 6.  Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.

Authors:  David A D'Alessio; Torsten P Vahl
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-06       Impact factor: 4.310

7.  The use of exenatide in islet transplant recipients with chronic allograft dysfunction: safety, efficacy, and metabolic effects.

Authors:  Tatiana Froud; Raquel N Faradji; Antonello Pileggi; Shari Messinger; David A Baidal; Gaston M Ponte; Pablo E Cure; Kathy Monroy; Armando Mendez; Gennaro Selvaggi; Camillo Ricordi; Rodolfo Alejandro
Journal:  Transplantation       Date:  2008-07-15       Impact factor: 4.939

8.  Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

Authors:  Loredana Farilla; Angela Bulotta; Boaz Hirshberg; Sergio Li Calzi; Nasif Khoury; Houtan Noushmehr; Cristina Bertolotto; Umberto Di Mario; David M Harlan; Riccardo Perfetti
Journal:  Endocrinology       Date:  2003-08-28       Impact factor: 4.736

9.  Improved beta-cell function after standardized weight reduction in severely obese subjects.

Authors:  Marie Guldstrand; Bo Ahrén; Ulf Adamson
Journal:  Am J Physiol Endocrinol Metab       Date:  2003-03       Impact factor: 4.310

10.  Consequences on beta-cell function and reserve after long-term pancreas transplantation.

Authors:  R Paul Robertson
Journal:  Diabetes       Date:  2004-03       Impact factor: 9.461

View more
  11 in total

1.  Reactive hypoglycaemia following GLP-1 infusion in pancreas transplant recipients.

Authors:  M R Rickels; A Naji
Journal:  Diabetes Obes Metab       Date:  2010-08       Impact factor: 6.577

2.  Effects of glucagon-like peptide 1 on glycemia control and its metabolic consequence after severe thermal injury--studies in an animal model.

Authors:  Chuan-an Shen; Shawn Fagan; Alan J Fischman; Edward E Carter; Jia-Ke Chai; Xiao-Ming Lu; Yong-Ming Yu; Ronald G Tompkins
Journal:  Surgery       Date:  2011-02-05       Impact factor: 3.982

3.  The ghrelin gene products and exendin-4 promote survival of human pancreatic islet endothelial cells in hyperglycaemic conditions, through phosphoinositide 3-kinase/Akt, extracellular signal-related kinase (ERK)1/2 and cAMP/protein kinase A (PKA) signalling pathways.

Authors:  E Favaro; R Granata; I Miceli; A Baragli; F Settanni; P Cavallo Perin; E Ghigo; G Camussi; M M Zanone
Journal:  Diabetologia       Date:  2012-01-10       Impact factor: 10.122

Review 4.  Use of glucagon-like peptide-1 agonists to improve islet graft performance.

Authors:  Yong Wang; Meirigeng Qi; James J McGarrigle; Brian Rady; Maureen E Davis; Pilar Vaca; Jose Oberholzer
Journal:  Curr Diab Rep       Date:  2013-10       Impact factor: 4.810

Review 5.  Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions.

Authors:  Michael R Rickels; R Paul Robertson
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 6.  Recovery of endocrine function after islet and pancreas transplantation.

Authors:  Michael R Rickels
Journal:  Curr Diab Rep       Date:  2012-10       Impact factor: 4.810

7.  Effect of Sitagliptin on Islet Function in Pancreatic Insufficient Cystic Fibrosis With Abnormal Glucose Tolerance.

Authors:  Andrea Kelly; Saba Sheikh; Darko Stefanovski; Amy J Peleckis; Sarah C Nyirjesy; Jack N Eiel; Aniket Sidhaye; Russell Localio; Robert Gallop; Diva D De Leon; Denis Hadjiliadis; Ronald C Rubenstein; Michael R Rickels
Journal:  J Clin Endocrinol Metab       Date:  2021-05-22       Impact factor: 5.958

Review 8.  Management of post-transplant diabetes.

Authors:  Ashley Therasse; Amisha Wallia; Mark E Molitch
Journal:  Curr Diab Rep       Date:  2013-02       Impact factor: 4.810

9.  Glucagon secretion and signaling in the development of diabetes.

Authors:  Herbert Y Gaisano; Patrick E Macdonald; Mladen Vranic
Journal:  Front Physiol       Date:  2012-09-04       Impact factor: 4.566

10.  GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation.

Authors:  Makoto Shigeto; Reshma Ramracheya; Andrei I Tarasov; Chae Young Cha; Margarita V Chibalina; Benoit Hastoy; Koenraad Philippaert; Thomas Reinbothe; Nils Rorsman; Albert Salehi; William R Sones; Elisa Vergari; Cathryn Weston; Julia Gorelik; Masashi Katsura; Viacheslav O Nikolaev; Rudi Vennekens; Manuela Zaccolo; Antony Galione; Paul R V Johnson; Kohei Kaku; Graham Ladds; Patrik Rorsman
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.